<DOC>
	<DOC>NCT00763061</DOC>
	<brief_summary>To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.</brief_summary>
	<brief_title>Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description>To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>≥18 years; IOP=1630mmHg OH or OAG with visual filed abnormality: 1. ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p &lt;5% on the prepapillary diameter plot, one of which must have p &lt;1%, 2. Glaucoma Hemifield Test outside normal limits, 3. Corrected Pattern Standard Deviation with p &lt;5% Previous damage of anterior chamber angle; ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) &lt;1.0; contact lens wearer; severe central field loss; uncontrolled cardiovascular, hepatic or renal disease; any medication within past 1 month.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>